vs
DELCATH SYSTEMS, INC.（DCTH）与REDWOOD TRUST INC（RWT）财务数据对比。点击上方公司名可切换其他公司
REDWOOD TRUST INC的季度营收约是DELCATH SYSTEMS, INC.的1.3倍（$25.9M vs $20.7M），REDWOOD TRUST INC净利率更高（77.2% vs -9.1%，领先86.4%），DELCATH SYSTEMS, INC.同比增速更快（37.3% vs -6.1%），过去两年DELCATH SYSTEMS, INC.的营收复合增速更高（157.0% vs -41.0%）
德尔卡斯系统公司是一家上市特种医药与医疗器械企业，主打研发经皮灌注技术，该技术可将高剂量化疗药物精准递送至人体特定器官或病变区域。公司总部位于纽约州昆斯伯里，在全球拥有28项专利的知识产权组合，其核心产品经皮肝灌注技术目前正针对肿瘤开展二期和三期临床试验。
Redwood Trust Inc是总部位于美国的专业房地产投资信托公司，主营住宅与商业抵押贷款、抵押贷款支持证券及房地产信贷类资产的投资管理，核心业务覆盖住宅抵押贷款发放、商业地产信贷和投资服务，客户以机构投资者和房地产市场参与者为主。
DCTH vs RWT — 直观对比
营收规模更大
RWT
是对方的1.3倍
$20.7M
营收增速更快
DCTH
高出43.4%
-6.1%
净利率更高
RWT
高出86.4%
-9.1%
两年增速更快
DCTH
近两年复合增速
-41.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.7M | $25.9M |
| 净利润 | $-1.9M | $20.0M |
| 毛利率 | 85.5% | — |
| 营业利润率 | -10.5% | — |
| 净利率 | -9.1% | 77.2% |
| 营收同比 | 37.3% | -6.1% |
| 净利润同比 | 44.2% | 402.6% |
| 每股收益（稀释后） | $-0.05 | $0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DCTHRWT
| Q4 25 | $20.7M | $25.9M | ||
| Q3 25 | $20.6M | $15.0M | ||
| Q2 25 | $24.2M | $13.8M | ||
| Q1 25 | $19.8M | $27.9M | ||
| Q4 24 | $15.1M | $27.6M | ||
| Q3 24 | $11.2M | $25.5M | ||
| Q2 24 | $7.8M | $67.4M | ||
| Q1 24 | $3.1M | $74.5M |
净利润DCTHRWT
| Q4 25 | $-1.9M | $20.0M | ||
| Q3 25 | $830.0K | $-7.7M | ||
| Q2 25 | $2.7M | $-98.5M | ||
| Q1 25 | $1.1M | $16.1M | ||
| Q4 24 | $-3.4M | $-6.6M | ||
| Q3 24 | $1.9M | $14.8M | ||
| Q2 24 | $-13.7M | $15.5M | ||
| Q1 24 | $-11.1M | $30.3M |
毛利率DCTHRWT
| Q4 25 | 85.5% | — | ||
| Q3 25 | 87.2% | — | ||
| Q2 25 | 86.3% | — | ||
| Q1 25 | 85.6% | — | ||
| Q4 24 | 85.9% | — | ||
| Q3 24 | 85.4% | — | ||
| Q2 24 | 80.4% | — | ||
| Q1 24 | 71.2% | — |
营业利润率DCTHRWT
| Q4 25 | -10.5% | — | ||
| Q3 25 | -1.9% | -9.0% | ||
| Q2 25 | 10.7% | -679.0% | ||
| Q1 25 | 3.2% | 80.2% | ||
| Q4 24 | 20.1% | -1.3% | ||
| Q3 24 | -11.2% | 86.1% | ||
| Q2 24 | -50.4% | 30.3% | ||
| Q1 24 | -327.4% | 41.3% |
净利率DCTHRWT
| Q4 25 | -9.1% | 77.2% | ||
| Q3 25 | 4.0% | -51.4% | ||
| Q2 25 | 11.2% | -712.0% | ||
| Q1 25 | 5.4% | 57.8% | ||
| Q4 24 | -22.5% | -24.0% | ||
| Q3 24 | 16.6% | 58.1% | ||
| Q2 24 | -176.9% | 23.0% | ||
| Q1 24 | -354.0% | 40.6% |
每股收益（稀释后）DCTHRWT
| Q4 25 | $-0.05 | $0.11 | ||
| Q3 25 | $0.02 | $-0.08 | ||
| Q2 25 | $0.07 | $-0.76 | ||
| Q1 25 | $0.03 | $0.10 | ||
| Q4 24 | $-0.06 | $-0.08 | ||
| Q3 24 | $0.06 | $0.09 | ||
| Q2 24 | $-0.48 | $0.10 | ||
| Q1 24 | $-0.45 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $43.5M | $255.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $111.2M | $982.6M |
| 总资产 | $123.6M | $23.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DCTHRWT
| Q4 25 | $43.5M | $255.7M | ||
| Q3 25 | $41.8M | $226.3M | ||
| Q2 25 | $34.4M | $302.0M | ||
| Q1 25 | $12.8M | $259.9M | ||
| Q4 24 | $32.4M | $245.2M | ||
| Q3 24 | $8.3M | $253.7M | ||
| Q2 24 | $14.8M | $275.6M | ||
| Q1 24 | $11.8M | $275.4M |
总债务DCTHRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $2.0M | — | ||
| Q2 24 | $4.5M | — | ||
| Q1 24 | $7.4M | $1.7B |
股东权益DCTHRWT
| Q4 25 | $111.2M | $982.6M | ||
| Q3 25 | $114.8M | $999.0M | ||
| Q2 25 | $105.0M | $1.1B | ||
| Q1 25 | $80.2M | $1.2B | ||
| Q4 24 | $68.7M | $1.2B | ||
| Q3 24 | $8.6M | $1.2B | ||
| Q2 24 | $4.2M | $1.2B | ||
| Q1 24 | $14.6M | $1.2B |
总资产DCTHRWT
| Q4 25 | $123.6M | $23.7B | ||
| Q3 25 | $124.3M | $22.6B | ||
| Q2 25 | $116.9M | $21.3B | ||
| Q1 25 | $87.3M | $19.9B | ||
| Q4 24 | $76.6M | $18.3B | ||
| Q3 24 | $31.7M | $18.4B | ||
| Q2 24 | $33.9M | $16.5B | ||
| Q1 24 | $36.1M | $15.1B |
负债/权益比DCTHRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 1.07× | — | ||
| Q1 24 | 0.50× | 1.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.2M | $-10.1B |
| 自由现金流经营现金流 - 资本支出 | $7.7M | — |
| 自由现金流率自由现金流/营收 | 37.1% | — |
| 资本支出强度资本支出/营收 | 2.7% | — |
| 现金转化率经营现金流/净利润 | — | -504.15× |
| 过去12个月自由现金流最近4个季度 | $21.0M | — |
8季度趋势，按日历期对齐
经营现金流DCTHRWT
| Q4 25 | $8.2M | $-10.1B | ||
| Q3 25 | $4.8M | $-2.7B | ||
| Q2 25 | $7.3M | $-2.1B | ||
| Q1 25 | $2.2M | $-2.0B | ||
| Q4 24 | $-1.0M | $-5.9B | ||
| Q3 24 | $-3.6M | $-2.1B | ||
| Q2 24 | $-4.5M | $-2.0B | ||
| Q1 24 | $-9.6M | $-954.2M |
自由现金流DCTHRWT
| Q4 25 | $7.7M | — | ||
| Q3 25 | $4.3M | — | ||
| Q2 25 | $6.9M | — | ||
| Q1 25 | $2.1M | — | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $-3.9M | — | ||
| Q2 24 | $-4.6M | — | ||
| Q1 24 | $-9.6M | — |
自由现金流率DCTHRWT
| Q4 25 | 37.1% | — | ||
| Q3 25 | 21.0% | — | ||
| Q2 25 | 28.5% | — | ||
| Q1 25 | 10.4% | — | ||
| Q4 24 | -8.2% | — | ||
| Q3 24 | -34.4% | — | ||
| Q2 24 | -58.6% | — | ||
| Q1 24 | -305.7% | — |
资本支出强度DCTHRWT
| Q4 25 | 2.7% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.6% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 1.9% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | 0.4% | — |
现金转化率DCTHRWT
| Q4 25 | — | -504.15× | ||
| Q3 25 | 5.75× | — | ||
| Q2 25 | 2.70× | — | ||
| Q1 25 | 2.06× | -120.92× | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.95× | -140.86× | ||
| Q2 24 | — | -126.56× | ||
| Q1 24 | — | -31.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DCTH
| HEPZATOKIT | $19.1M | 92% |
| CHEMOSAT | $1.7M | 8% |
RWT
暂无分部数据
